FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318578654> ?p ?o ?g. }

• W4318578654 endingPage "i1007" @default.
• W4318578654 startingPage "i1006" @default.
• W4318578654 abstract "Abstract Background Infliximab(IFX) subcutaneous(SC) was developed as a novel formulation biosimilar added to the intravenous(IV) infliximab. Infliximab is one of the most effective treatments in IBD and approval of subcutaneous formulation was expected to bring greater patient convenience, yet it had to overcome its hurdles in Health Technology Assessment (HTA) in the absent of the SC originator. This research aims to evaluate patient access to IFX SC based on time-to-reimbursement decision post market authorization in July of 2021. Methods The pricing database, IQVIA MIDAS® data and epidemiology data were combined to analyze patient access in 32 countries. We evaluated 1) status of the reimbursement 2) volume consumed in a country 3) average period from marketing authorisation to positive reimbursement decision 4) reason for delayed access. Results Since the market authorization, positive reimbursement decisions were made in 18 countries among 31 European countries including UK. Among them, patients who reside in 15 countries had records of utilization of IFX SC in the year of 2022. About 74.76% of IBD patients is eligible for reimbursement of CT-P13 SC among the assumed 1,023,765 IBD patients in Europe. Average time from market authorisation to positive reimbursement decision by health authorities were 9 months(2-17) in the case of IFX SC which suggests delayed reimbursement compared to biosimilars. Although most of the European countries offered shortened or simplified HTA pathways to biosimilars, most of the countries did not have clear guidance on pricing of the novel biosimilars. Several countries failed to provide IFX SC after a positive reimbursement decision because the procurement system failed to differentiate a novel biosimilar with different strength and form from the existing biosimilars in same molecule. This may have deterred the market entry; countries where adopted national tender grouped IFX SC with IFX IV(Norway, Hungary) or extended procurement basket to all available IBD treatment(Denmark and Lithuania). Figure: Reimbursement status of infliximab subcutaneous in European countries Conclusion There are apparent differences in patient access to IFX SC among European countries. Biosimilars promises to bring improved patient access to biologics, however, pricing of bio-betters or bio-innovators could be convoluted that efforts are still warranted in order to bring the drug into the market within shortest possible time. Although IBD treatment options are expanding, IFX is still widely used. Adding another SC treatment may improve patient convenience and quality of life and thus, overall improved access to the drug is imperative for equitable use." @default.
• W4318578654 created "2023-01-31" @default.
• W4318578654 creator A5015448261 @default.
• W4318578654 creator A5056523193 @default.
• W4318578654 creator A5083303353 @default.
• W4318578654 date "2023-01-30" @default.
• W4318578654 modified "2023-10-16" @default.
• W4318578654 title "P888 Evaluating patient access to infliximab subcutaneous in inflammatory bowel disease" @default.
• W4318578654 doi "https://doi.org/10.1093/ecco-jcc/jjac190.1018" @default.
• W4318578654 hasPublicationYear "2023" @default.
• W4318578654 type Work @default.
• W4318578654 citedByCount "0" @default.
• W4318578654 crossrefType "journal-article" @default.
• W4318578654 hasAuthorship W4318578654A5015448261 @default.
• W4318578654 hasAuthorship W4318578654A5056523193 @default.
• W4318578654 hasAuthorship W4318578654A5083303353 @default.
• W4318578654 hasBestOaLocation W43185786541 @default.
• W4318578654 hasConcept C108759981 @default.
• W4318578654 hasConcept C126322002 @default.
• W4318578654 hasConcept C159110408 @default.
• W4318578654 hasConcept C160735492 @default.
• W4318578654 hasConcept C162324750 @default.
• W4318578654 hasConcept C2777138892 @default.
• W4318578654 hasConcept C2779134260 @default.
• W4318578654 hasConcept C2779598192 @default.
• W4318578654 hasConcept C2779703844 @default.
• W4318578654 hasConcept C38652104 @default.
• W4318578654 hasConcept C41008148 @default.
• W4318578654 hasConcept C50522688 @default.
• W4318578654 hasConcept C512399662 @default.
• W4318578654 hasConcept C59491497 @default.
• W4318578654 hasConcept C71924100 @default.
• W4318578654 hasConceptScore W4318578654C108759981 @default.
• W4318578654 hasConceptScore W4318578654C126322002 @default.
• W4318578654 hasConceptScore W4318578654C159110408 @default.
• W4318578654 hasConceptScore W4318578654C160735492 @default.
• W4318578654 hasConceptScore W4318578654C162324750 @default.
• W4318578654 hasConceptScore W4318578654C2777138892 @default.
• W4318578654 hasConceptScore W4318578654C2779134260 @default.
• W4318578654 hasConceptScore W4318578654C2779598192 @default.
• W4318578654 hasConceptScore W4318578654C2779703844 @default.
• W4318578654 hasConceptScore W4318578654C38652104 @default.
• W4318578654 hasConceptScore W4318578654C41008148 @default.
• W4318578654 hasConceptScore W4318578654C50522688 @default.
• W4318578654 hasConceptScore W4318578654C512399662 @default.
• W4318578654 hasConceptScore W4318578654C59491497 @default.
• W4318578654 hasConceptScore W4318578654C71924100 @default.
• W4318578654 hasIssue "Supplement_1" @default.
• W4318578654 hasLocation W43185786541 @default.
• W4318578654 hasOpenAccess W4318578654 @default.
• W4318578654 hasPrimaryLocation W43185786541 @default.
• W4318578654 hasRelatedWork W2155761001 @default.
• W4318578654 hasRelatedWork W2298699284 @default.
• W4318578654 hasRelatedWork W2411046411 @default.
• W4318578654 hasRelatedWork W2545612137 @default.
• W4318578654 hasRelatedWork W2993668731 @default.
• W4318578654 hasRelatedWork W3001258617 @default.
• W4318578654 hasRelatedWork W3112600915 @default.
• W4318578654 hasRelatedWork W3199009715 @default.
• W4318578654 hasRelatedWork W4297926687 @default.
• W4318578654 hasRelatedWork W4318578654 @default.
• W4318578654 hasVolume "17" @default.
• W4318578654 isParatext "false" @default.
• W4318578654 isRetracted "false" @default.
• W4318578654 workType "article" @default.